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The Tumor Bank at The Children’s Hospital at Westmead was established in 1998 with the purpose of 
facilitating research into childhood malignancy through the active provision of well annotated, ethically 
collected tissue samples and providing a pathway for the Children Hospital at Westmead to engage in 
 leading research initiatives, supporting international investigations and clinical trials. Within 20 years 
practice as a single institute biorepository, The Tumour Bank has established standard operating  procedures 
for collection of tissue, blood and bone marrow that were integrated into routine patient management 
systems. In addition, three main operational areas have been developed: collection of biospecimens and 
written consent; management of clinical data and biospecimen inventory database; and implementation 
of an open access policy to support childhood cancer research around the world. Regulatory oversight is 
provided by the Tumour Bank Committee, Human Research Ethics Committee and Governance Department. 
This concerted effort has resulted in collecting 20340 specimens from 3788 patients within 20 years, and 
The Tumour bank has supported over 108 national and international research projects, and contributed to 
over 70 peer-reviewed publications to date, with a mean time–to-publication of 19.1 ± 9.0 months and 
average Impact Factor of 6.11 ± 4.53. In conclusion, the Children’s Hospital at Westmead Tumour Bank has 
demonstrated a sustained single institutional biorepository model for facilitating translational research 
of rare cancer. It has provided strong evidence that integration of a single institutional biobank into 
standard clinical practices would be the long-term pathway of valuable bio-resource for rare cancer 
research.




Paediatric cancers, as rare diseases, require long term 
 collection strategies to ensure comprehensive accrual 
rates. Paediatric research has been hampered for years 
due to the lack of quality paediatric biospecimen, and 
biobanking is the only economical and efficient solution 
to meet future research needs.
The Children Hospital at Westmead (CHW) is the 
 largest paediatric healthcare centre in NSW, Australia 
with its Oncology Department treating an average of 150 
new patients each year. To support paediatric research, 
its Tumour Bank CHWTB was founded in 1998 with 
 benefactor funds donated to CHW oncology  departments. 
Presently CHWTB is partly funded by core health funding, 
research infrastructure grants and benefactors [1]. As 
a single institution biorepository being embedded in 
 hospital clinical pathways, CHWTB collects residual to 
diagnostic requirements from all the cancer patients. 
CHWTB is closely linked to the primary tissue collection 
point in the pathology department, which minimises 
the daily operational cost and ensures consistency and 
efficiency of practice.
The purpose of the CHWTB is to open an avenue for 
CHW to engage in leading translational research  initiatives, 
support international investigations and clinical trials, 
and most importantly promote paediatric cancer research 
via the active provision of ethically collected samples with 
full clinical annotation. Via professional and standardized 
biobanking activity, CHWTB will improve the deeper 
understanding of paediatric cancer, which is fundamental 
to a improved healthcare for children with cancer.
In the 19 years of operation the CHWTB has collected 
20340 specimens from 3788 patients. CHWTB has actively 
pursued researcher groups exploring leading translational 
research in paediatric cancer and we have since facilitated 
108 projects both in Australia and other countries around 
the world (41% from Australia, 26% from the United States, 
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7% from the United Kingdom, 4% from New Zealand, 3% 
from Canada and 19% from the rest of the world), which 
have generated over 70 publications correspondingly [2]. 






Biological samples and associated data.
Context
Spatial coverage
The Tumour Bank at The Children Hospital at Westmead 





Start from 1998 to present, no end date.




As an embedded facility within the hospital, the CHWTB 
can collect resected tumours, biopsies, bone marrow 
and blood samples via the pathology or haematology 
departments during the normal course of diagnosis 
and treatment that are in excess of clinical/diagnostic 
requirements collection. To ensure consistent and 
 comprehensive collection of specimens, standard operating 
procedures (SOPs) and interdepartmental pathways for 
samples have been developed. These SOPs outline CHWTB 
staff’s daily practice and our operational relationships 
and processes with oncology, surgery, histopathology 
and haematology departments in CHW [3]. All the SOPs 
followed the guideline of best practice of ISBER [4]. 
Informed Consent Management and Ethics Committee 
Compliance
Being within a public hospital, the management of our 
consenting practices has been simplified profoundly 
by allowing consent to occur during routine patient 
 consultation, patient admission for treatment or after 
a sample has been collected for diagnosis or clinical 
 management. Patients are consented after a diagnosis 
of cancer has been obtained, which typically means that 
a biospecimen was obtained for diagnostic testing, the 
residual of which may be made available to the CHWTB upon 
donor consent. Our practice allows consent to be sought 
by registrars, clinical fellows, staff specialists and clinical 
research associates during the normal course of clinical 
management of the patients, which has dramatically 
lessen the impact of different staffing arrangements on 
consenting rates. Ideally we seek consent during patient 
consultation of treatment regimens to be provided. 
Our consenting SOPs strictly follow paediatric biobank 
consent guidelines [5] as summarized below: 
• Potential donors, their parents or legal guardians must 
be informed by written documents that the potential 
intended use of the sample will be for research 
 projects only.
• Parents or legal guardians of children under 12 years 
of age are asked to make written and broad consent 
to allow future unspecific studies. However, donors 
reserve the right to withdraw their specimen at any 
time.
• Assent from children >12 years of age can be 
requested and confirmed when deemed appropriate 
by parent or consenter. 
• Whilst it is not yet obligatory to re-consent patients 
when they have reached the age of majority, that is 
18 years and over, the CHWTB may re-consent and 
remind patients about samples already stored in the 
biobank as opportunity to do so occurs (eg. During 
late effects clinics).
• The specimen mustn’t be used for any other  purpose 
than valid biomedical research, This excludes 
 applications that are purely commercial in nature.
• Both the specimens and matching clinical data must 
be de-identified before being released to researchers. 
In addition to the consideration of protecting donor 
privacy, confidentiality and cultural sensitivities of 
children are also considered.
Additional mechanisms have been developed that allow 
us to seek consent from patients whose consultation 
regarding donation of tissue to the CHWTB could not be 
sought during their admission to hospital, This includes 
use of letters to follow up remote patients or working with 
bereavement counsellors to seek consent from families 
where a child may have died. 
Research Review and Governance
The researchers must formally apply through the Tumour 
Bank Committee to access the samples. The Tumour 
Bank committee will review the scientific feasibility of 
the  project. Evidence of local or institutional human 
ethics committee approval must be presented with the 
 application prior to the samples release to the applicants. 
Our current consent form has a tick box where donors 
can express their wishes with regards to return of the 
 incidental findings. In the event that the committee 
 identifies that incidental findings are likely their return will 
be specified to the researchers, as our current  practice is to 
notify and transfer the responsibility to a treating clinician 
to determine further course of action. This is reflected in 
our Consent form and Patient Information Sheet.
Public Awareness
The consent process CHWTB is also supplemented by the 
provision the CHWTB “Newsletter” that describes basic 
processes and research that has been supported by our 
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samples [6]. CHWTB consents for unspecified research, 
any future matched blood collection, and serial leukaemia 
bone marrow samples. CHWTB obtains all samples ethically 
and written consent has been recorded for all samples.
Data Linkage
Another advantage of being a biobank embedded with the 
hospital is the clinical data linkage. CHWTB only collects 
essential data at the collection point and enters into our 
database. If any specified data is missing at the collection 
point, it is obtained from the hospital database since the 
full data access is available, which includes demographic 
information, laboratory tests, diagnosis, and treatment, 
etc. All the diagnosis is in ICCC and ICD-O coding for 
 international standardization. In addition, as it is part of the 
Sydney Children’s Hospital Network, the network security 
can be accomplished by hospital firewall. All the data is de-
identified before being released to any researchers.
Stabilization/preservation
• Ethylenediaminetetraacetic acid (EDTA), Acid-Citrate-
Dextrose (ACD), RPMI
• Snap freeze tissue in liquid nitrogen
Type of long-term preservation




• Room temperature (bone marrow smears)
• −20°C (for clinical trial samples)
• −80°C (tissue, blood, bone marrow, cerebrospinal fluid)
• −160°C (cells)
Shipping temperature from patient/source to 
preservation or research use 
Room temperature (18–25°C)
Shipping temperature from storage to research use 
• Room temperature (FFPE sections) 
• −78°C dry ice (DNA, RNA, blood & Bone marrow) 
Quality assurance measures
• SOPs will be followed throughout all the sample 
 collection and processing steps.
• Quality of FFPE tissue will be checked morphologi-
cally and immunohistochemically to assure proper 
 tissue processing and fixation and therefore sufficient 
 antigenic preservation.
• The tumour diagnosis (including grading using the 
most current diagnosis system), percentage of tumour, 
percentage of stroma, and percentage of necrosis will 
be assessed by histopathologist.
• DNA will be quantified by nano drop and picogreen.
• DNA&RNA will be checked by Agilent 2100 bioanalyzer.
• Specific biomarkers will be checked according to 
 specific downstream request.
• Compliance with local ethics/governance and 
national laws, eg. Human Tissue Act (2004) [7].
Source of associated data 
Hospital databases—Oncology Patient Register,  pathology 
report, clinical test results, clinical notes, treatment 
 protocols, etc.
Ethics statement 
The ethical approval from the CHWTB to meet its stated 
purpose in supporting national and international research 
into paediatric cancer through the provision of ethically 
collected biospecimens has provided by Sydney Children’s 
Hospitals Network Human Research Ethics Committee in 
New South Wales, Australia. The approval was initiated in 
1998, and reviewed every 4 years since. 








170 Hawkesbury Rd, Westmead, NSW, Australia 2145.
Bioresource contact 








Paediatric cancers. These include samples collected 
from leukaemia patients (34%) collected at diagnosis, 
 remission, relapse and during other significant treat-
ment time points, solid tumours available include all 
cancers that appear in children, the majority being lym-
phomas (10%), brain tumours (16%), carcinomas (2%), 
 neuroblastomas (8%), sarcomas (10%), liver and kid-
ney tumours (6%), germ cell tumours and other rare 
tumours (14%).




Disease status of patients/source 
Paediatric cancers.
Clinical characteristics of patients/source 
Paediatric tumour samples with full clinical data, de-
identified before released to researchers.
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Size of the bioresource 
3788 patients as at 3/5/2017. 
On-going recruitment of ~150 new patients per annum. 
Collection is ongoing and has no definite end date. 
Vital state of patients/source 
Alive/Deceased.
Clinical diagnosis of patients/source 
Variable. 
Pathology diagnosis 
Variable—representing over 50 types and subtypes of 
 paediatric cancers.
Control samples 
CHWTB doesn’t collect control samples from healthy 
 children. As consent allows, germ line samples (peripheral 
blood) from the majority of patients with solid tumours 
have been collected, stored and are used as matched con-
trol samples for comparison with tumour tissue.
Biospecimen type 
CHWTB provides a different variety of biospecimen 
 including serum, plasma, DNA, RNA, cerebrospi-
nal fluid, fresh frozen tissue, FFPE tissue and Tissue 
Microarray.
Release date 
Open since 1998, applications received from interested 
researchers.
Access criteria 
Via active or passive communication with researcher, 
the CHWTB will capture the research interest of the 
researcher and provide them the number and type of 
samples  suitable for the researcher. Researchers request 
access to the CHWTB sample resource through an 
application  mechanism. Applications need to be 
 accompanied by approval from the researchers’ local 
host ethics committee or governance system, evidence 
of funding availability to see the project through to 
completion and a scientifically valid research proposal. 
The applications are reviewed by the CHWTB Committee 
for compliance to our  requirements, scientific  quality, 
researcher  institution track record and our ability to 
 support the study through sample provision, tissue han-
dling expertise. Once approved by the committee, CHWTB 
will release the samples. CHWTB doesn’t charge anything 
for the samples, but the researchers will need to pay for 
the shipments.
(4) Reuse potential 
Specimen from the same patient may be used in several 
different projects. 
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